Aurisco PharmaceuticalLtd Past Earnings Performance
Past criteria checks 4/6
Aurisco PharmaceuticalLtd has been growing earnings at an average annual rate of 19.1%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 19.1% per year. Aurisco PharmaceuticalLtd's return on equity is 15%, and it has net margins of 23.9%.
Key information
19.1%
Earnings growth rate
16.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 19.1% |
| Return on equity | 15.0% |
| Net Margin | 23.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Investors Shouldn't Be Too Comfortable With Aurisco PharmaceuticalLtd's (SHSE:605116) Earnings
May 12
Recent updates
Is Aurisco PharmaceuticalLtd (SHSE:605116) A Risky Investment?
Sep 19Is Now The Time To Put Aurisco PharmaceuticalLtd (SHSE:605116) On Your Watchlist?
Aug 14Investors Interested In Aurisco Pharmaceutical Co.,Ltd.'s (SHSE:605116) Earnings
Jun 28Aurisco PharmaceuticalLtd (SHSE:605116) Has A Pretty Healthy Balance Sheet
Jun 07Investors Shouldn't Be Too Comfortable With Aurisco PharmaceuticalLtd's (SHSE:605116) Earnings
May 12Here's Why We Think Aurisco PharmaceuticalLtd (SHSE:605116) Might Deserve Your Attention Today
Apr 22Revenue & Expenses Breakdown
How Aurisco PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,428 | 341 | 296 | 146 |
| 30 Jun 24 | 1,441 | 382 | 319 | 146 |
| 31 Mar 24 | 1,296 | 326 | 286 | 140 |
| 31 Dec 23 | 1,263 | 289 | 274 | 137 |
| 30 Sep 23 | 1,162 | 257 | 251 | 132 |
| 30 Jun 23 | 1,052 | 190 | 209 | 118 |
| 31 Mar 23 | 1,091 | 216 | 191 | 111 |
| 31 Dec 22 | 1,008 | 211 | 179 | 117 |
| 30 Sep 22 | 983 | 222 | 163 | 110 |
| 30 Jun 22 | 911 | 202 | 152 | 97 |
| 31 Mar 22 | 836 | 177 | 142 | 90 |
| 31 Dec 21 | 803 | 169 | 136 | 69 |
| 30 Sep 21 | 767 | 151 | 110 | 57 |
| 30 Jun 21 | 741 | 137 | 104 | 54 |
| 31 Mar 21 | 727 | 140 | 97 | 49 |
| 31 Dec 20 | 721 | 157 | 95 | 47 |
| 30 Sep 20 | 688 | 206 | 105 | 49 |
| 31 Dec 19 | 582 | 186 | 94 | 35 |
| 31 Dec 18 | 575 | 137 | 88 | 25 |
| 31 Dec 17 | 544 | 45 | 152 | 24 |
| 31 Dec 16 | 590 | 87 | 185 | 18 |
Quality Earnings: 605116 has a high level of non-cash earnings.
Growing Profit Margin: 605116's current net profit margins (23.9%) are higher than last year (22.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 605116's earnings have grown by 19.1% per year over the past 5 years.
Accelerating Growth: 605116's earnings growth over the past year (32.5%) exceeds its 5-year average (19.1% per year).
Earnings vs Industry: 605116 earnings growth over the past year (32.5%) exceeded the Pharmaceuticals industry -2.5%.
Return on Equity
High ROE: 605116's Return on Equity (15%) is considered low.